Overview

SKB500 Combinations in Patients With Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Phase:
PHASE2
Details
Lead Sponsor:
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Treatments:
Carboplatin
Etoposide
Immune Checkpoint Inhibitors